Alpha-9 Theranostics
San Diego, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $75M
Overview
Developing precision radiopharmaceuticals that combine diagnostic imaging and targeted radiotherapy for cancer.
OncologyDiagnostics
Technology Platform
A peptide-based platform for discovering and developing paired diagnostic and therapeutic radiopharmaceuticals that target specific proteins on cancer cells.
Funding History
1Total raised:$75M
Venture$75M
Opportunities
Riding the wave of validated theranostics in oncology, with potential for breakthrough efficacy in hard-to-treat solid tumors using novel peptide targets.
Risk Factors
High competition for validated isotopes and manufacturing capacity, alongside the preclinical risk of novel targets failing to translate in humans.
Competitive Landscape
Enters a hotly competitive radiopharmaceutical space dominated by large pharma (Novartis, Bayer) and numerous biotechs, requiring highly differentiated targets.